FDA Approves Aegerion's Cholesterol Drug With Strongest Warning

Reuters (12/24/12) Ail, Pallavi
Aegerion Pharmaceuticals has announced that the Food and Drug Administration (FDA) approved its drug Juxtapid as an alternative treatment for patients who have a genetic predisposition to high cholesterol. Scheduled for launch in January, Juxtapid will carry a boxed warning and will be available only through a restricted program due to risk of liver damage. The company plans to conduct a post-approval study to test Juxtapid's long-term safety and efficacy.

Read the complete article


Share |

Sponsor Highlights

inPharmacyJobs